PMPRB Summary of VCUs & Orders - 2007
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| December 20, 2007 |
Dovobet |
LEO Pharma Inc. |
See VCU |
Yes |
$870,425.68 |
|
Expiration 01/2014 |
| September 26, 2007 |
Zemplar |
Abbott Laboratories Limited |
See VCU |
Yes |
$58,741.67 |
$58,741.67 |
12/2011 |
| September 13, 2007 |
OctreoScan |
Bristol Myers Squibb Canada Co. |
See VCU |
Yes |
|
$387,181.87 |
12/2009 |
| June 28, 2007 |
Forteo |
Eli Lilly Canada Inc. |
|
2007 MNE: $204.8097 |
$333,629.25 |
$333,629.25 |
Expiration 08/2019 |
| June 4, 2007 |
Risperdal Consta3 |
Janssen-Ortho Inc. |
25 mg :157.4; 37.5 mg : 155.8; 50 mg : 155.8 |
Yes |
$4,386,172.99 |
$4,386,172.99 |
Expiration 05/2017 |
| May 14, 2007 |
Airomir4 |
3M Canada Company5 |
|
See VCU for details |
$485,498.58 |
$485,498.58 |
Expiration 04/2014 |
| ORDER |
| Sept. 17, 2007 |
Dovobet |
LEO Pharma Inc |
Yes |
Yes |
$3,736,398.71 |
$3,736,398.71 (by October 18, 2007) |
Sept. 8, 2009 |
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.
3. Notice of Hearing issued on January 30, 2006.
4. Notice of Hearing issued on February 20, 2006.
5. As of December 29, 2006, Graceway Canada Company is the reporting company following sale of marketing rights for Airomir.